Efficacy and Safety of Rituximab Therapy in Neuromyelitis Optica Spectrum Disorders: A Systematic Review and Meta-analysis.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Neuromyelitis optica spectrum disorders (NMOSDs) are autoimmune astrocytopathies characterized by predominant involvement of the optic nerves and spinal cord. In most patients, an IgG autoantibody binding to astrocytic aquaporin 4, the principal water channel of the central nervous system, is detected. Rituximab, a chimeric monoclonal antibody specific for the CD20 B-lymphocyte surface antigen, has been increasingly adopted as a first-line off-label treatment for patients with NMOSDs.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): JAMA Neurol

Title: JAMA neurology

Publisher: American Medical Association (AMA)

ISSN (Electronic): 2168-6157

ISSN (Print): 2168-6149

Publication date (Electronic): Nov 01 2016

Volume: 73

Issue: 11

Affiliations

[1 ] Institute of Neurology, Department of Neuroscience, Fondazione "A. Gemelli," Catholic University, Rome, Italy.

[2 ] Institute of Neurology, Department of Neuroscience, Fondazione "A. Gemelli," Catholic University, Rome, Italy2Don Gnocchi ONLUS Foundation, Milan, Italy.

Article

Publisher Item ID: 2553834

DOI: 10.1001/jamaneurol.2016.1637

PubMed ID: 27668357

SO-VID: 7a3d51df-7583-45e7-9f9b-7b4b0c4ec636

History

Data availability:

Comments

Comment on this article

scite_

Cited by 107

See all cited by

- Version 1